Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian stock markets open weak
Tue, 15 Nov 09:30 am

Asian stock markets have opened the day on a weak note with stock markets in Hong Kong (down 1%), Indonesia (down 0.5%) and South Korea (down 0.5%) leading the losses. The Indian stock market have also opened the day on a weak note. Stocks in the realty, power and banking space are leading the losses. However, healthcare stocks are trading firm.

The BSE-Sensex is trading lower by 30 points (0.2%), while the NSE-Nifty is down by around 12 points (0.2%). Mid and small cap stocks are also trading in the red as well, with the BSE Mid cap and BSE Small cap indices down by 0.8% and 0.3% respectively. The rupee is trading at 50.43 to the US dollar.

Auto stocks have opened the day on a weak note with Tata Motors and Mahindra & Mahindra leading the losses. India's largest car manufacturer Maruti Suzuki has hiked the price s of its diesel cars by as much as Rs 10,000. The company cited rising input costs and an appreciating yen as the main reasons for the increase. Due to about Rs 30 difference in petrol and diesel prices, there has been a significant increase in demand for diesel cars in recent months. Maruti's new Swift model has a booking of at least 100,000 units, with more than 85% being for diesel variants. The company has hiked the price of the Ritz diesel model by Rs 2,000, whereas other models have witnessed a rise of Rs 10,000 in prices.

Pharma stocks have opened the day on a mixed note with Cipla leading with significant gains. However, Dishman Pharma and Aurobindo Pharma are trading in the red. India's second largest drug manufacturer by domestic sales, Cipla, has declared its results for the second quarter of financial year 2011-12 (2QFY12). The company has reported a 7.8% YoY growth in sales during the quarter ended September 2011. Domestic sales were higher by 12% YoY. Exports to Africa were higher by 41% YoY. However, sales in the Middle East were affected due to adverse market conditions. The company reported a higher growth of 17.5% YoY in net profits on account of cost savings and a rise in interest income.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian stock markets open weak". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.